Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Sponsor: Genmab
Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
23
Start Date
2024-11-13
Completion Date
2028-06-29
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
GEN1286
Specified dose on specified days.
Locations (4)
Massachusetts General Hospital
Boston, Massachusetts, United States
START Midwest
Grand Rapids, Michigan, United States
START San Antonio
San Antonio, Texas, United States
START Mountain Region
West Valley City, Utah, United States